AI drug developer Insilico Medicine secures US10M deal for Parkinson’s treatment

USA—Insilico Medicine, an artificial intelligence-powered drug discovery company, has secured a US10 million upfront payment from Chinese biotech Hygtia Therapeutics.

The deal grants Hygtia half of the rights to develop and commercialize ISM8969, a brain-penetrant NLRP3 inhibitor currently in preclinical development.

The partnership divides responsibilities between the two companies at different stages of drug development.

Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.

Following the completion of this early-stage trial, Hygtia will assume control of subsequent studies and guide the therapy through regulatory approval processes toward potential commercialization.

Beyond the initial payment, Insilico stands to receive up to USD56 million in milestone payments as the drug candidate progresses through various development stages.

These milestone-based payments reflect the achievement of specific regulatory and clinical objectives throughout the drug development journey.

Growing Interest in NLRP3 Inhibition

The pharmaceutical industry has shown increasing enthusiasm for NLRP3 inhibitors as potential treatments for neuroinflammatory and cardiometabolic diseases over the past year.

This therapeutic approach targets a specific protein complex involved in inflammatory responses, which researchers believe plays a significant role in various disease processes.

The growing interest became particularly evident earlier this month when Eli Lilly acquired Ventyx Biosciences for USD1.2 billion.

This acquisition followed a phase 2 study demonstrating that Ventyx’s lead NLRP3 inhibitor produced improvements in Parkinson’s symptoms among trial participants.

The same experimental therapy also showed promise in cardiovascular applications, reducing levels of a biomarker associated with stroke and other serious cardiovascular risks by nearly 80% within one week in a separate midstage study.

AI-Driven Drug Discovery

Insilico developed ISM8969 using Chemistry42, its proprietary generative chemistry engine.

The company reports that preclinical data have demonstrated the molecule’s strong efficacy and favorable safety profile across various disease models.

The therapy has also shown significant anti-inflammatory activity and achieves desirable penetration of the blood-brain barrier, a critical feature for drugs targeting neurological conditions.

Dr. Ren Feng, Insilico’s co-CEO and Chief Scientific Officer, emphasized the therapeutic potential of this approach.

“Targeting neuroinflammation via NLRP3 represents a scientifically sound and high-potential approach to treating neurodegenerative and age-related diseases,” Feng stated.

He acknowledged that developing a safe molecule capable of crossing the blood-brain barrier presents a formidable obstacle for drug developers.

However, Feng expressed confidence that Insilico’s generative AI platform has enabled the design of a molecule specifically engineered to overcome this barrier.

Strategic Partnerships

Insilico, which completed its public listing on the Hong Kong Stock Exchange last month, has successfully attracted partnerships with major pharmaceutical companies.

The company’s AI-enabled drug discovery technology has drawn interest from Sanofi, Pfizer, Menarini Group, and Boehringer Ingelheim. Most recently, Eli Lilly signed a deal worth over USD 100 million in November.

Hygtia Therapeutics, founded last August following incubation by Fosun Pharma, views this agreement as a pivotal step in its global expansion strategy.

The biotech company stated that this partnership aligns with its strategy to build an innovative neuroscience pipeline by acquiring high-quality assets.

Feng added that the combined efforts of both companies should accelerate the clinical development of ISM8969 to address significant unmet medical needs in the treatment of neurodegenerative diseases.